Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 7/20 | 0.72 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27590188 | 0.88 | AGTR2 (0.59) | AGTR2AGTR1CYP2C9 | |
| SCHEMBL709767 | 0.87 | AGTR2 (0.74) | AGTR2AGTR1MEN1GMNNUSP2 | |
| SCHEMBL710640 | 0.87 | AGTR2 (0.75) | AGTR2AGTR1MEN1GMNNUSP2 | |
| SCHEMBL707904 | 0.86 | AGTR2 (0.76) | AGTR2AGTR1MEN1GMNNUSP2 | |
| Buloxibutid SCHEMBL557591 | 0.83 | AGTR2 (1.00) | AGTR2AGTR1CYP2C9 | |
| SCHEMBL23121018 | 0.83 | AGTR2 (1.00) | AGTR2AGTR1MEN1GMNNUSP2 | |
| Buloxibutid SCHEMBL30718088 | 0.83 | AGTR2 (0.98) | AGTR2AGTR1CYP2C9 | |
| Buloxibutid SCHEMBL26934181 | 0.83 | AGTR2 (0.98) | AGTR2AGTR1CYP2C9 | |
| SCHEMBL557971 | 0.83 | AGTR2 (0.77) | AGTR2AGTR1MEN1GMNNUSP2 | |
| SCHEMBL29106461 | 0.82 | AGTR2 (0.84) | AGTR2AGTR1MEN1GMNNUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1529697-B | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB | 2010-09-22 | — | — | CN | claimed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | claimed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | claimed |
| CN-1529697-A | Tricyclic compounds useful as angiotensin II agonists | ά�ƶ�ҩ�﹫˾ | 2004-09-15 | — | — | CN | claimed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | claimed |
| US-8124638-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| CN-1529697-B | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB | 2010-09-22 | — | — | CN | disclosed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | disclosed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | disclosed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| CN-1529697-A | Tricyclic compounds useful as angiotensin II agonists | ά�ƶ�ҩ�﹫˾ | 2004-09-15 | — | — | CN | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | AGTR2 2/4885AGTR1 1/4885MEN1 2320/4885 |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885AGTR1 2/4885MEN1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.